The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

Michael Roche, Laura Parisi, Linda Li, Amy Knehans, Rebecca Phaeton, Joshua P. Kesterson

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaT M) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

Original languageEnglish (US)
Pages (from-to)8-13
Number of pages6
JournalOncology Reviews
Volume12
Issue number1
DOIs
StatePublished - Jan 30 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review'. Together they form a unique fingerprint.

Cite this